DrugPatentWatch Database Preview
Acorda Company Profile
What is the competitive landscape for ACORDA, and what generic alternatives to ACORDA drugs are available?
ACORDA has two approved drugs.
There are twenty-three US patents protecting ACORDA drugs.
There are one hundred and fifty-four patent family members on ACORDA drugs in thirty countries and eighteen supplementary protection certificates in nine countries.
Summary for Acorda
| International Patents: | 154 |
| US Patents: | 23 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
| Patent Litigation for Acorda: | See patent lawsuits for Acorda |
| PTAB Cases with Acorda as patent owner: | See PTAB cases with Acorda as patent owner |
Drugs and US Patents for Acorda
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acorda | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | RX | Yes | Yes | 8,685,442 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Acorda | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | RX | Yes | Yes | 7,146,978 | ➤ Sign Up | ➤ Sign Up | ||||
| Acorda | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | RX | Yes | Yes | 6,921,528 | ➤ Sign Up | ➤ Sign Up | ||||
| Acorda | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | RX | Yes | Yes | 9,393,210 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Acorda
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Acorda | AMPYRA | dalfampridine | TABLET, EXTENDED RELEASE;ORAL | 022250-001 | Jan 22, 2010 | 5,370,879 | ➤ Sign Up |
| Acorda | AMPYRA | dalfampridine | TABLET, EXTENDED RELEASE;ORAL | 022250-001 | Jan 22, 2010 | 5,540,938 | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for ACORDA drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Tablets | 10 mg | ➤ Subscribe | 2014-01-22 |
International Patents for Acorda Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 4897198 | ➤ Sign Up |
| European Patent Office | 2377536 | ➤ Sign Up |
| Russian Federation | 2275900 | ➤ Sign Up |
| Singapore | 10201706465X | ➤ Sign Up |
| Country | Patent Number | Estimated Expiration |
Supplementary Protection Certificates for Acorda Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2377536 | 13C0033 | France | ➤ Sign Up | PRODUCT NAME: FAMPRIDINE OU L'UN DE SES DERIVES; REGISTRATION NO/DATE: EU/1/11/699/001-002 20110725 |
| 2377536 | PA2013015,C2377536 | Lithuania | ➤ Sign Up | PRODUCT NAME: FAMPRIDINUM; REGISTRATION NO/DATE: EU/1/11/699/001 - EU/1/11/699/002 20110720 |
| 1732548 | PA2012001,C1732548 | Lithuania | ➤ Sign Up | PRODUCT NAME: FAMPRIDINUM; REGISTRATION NO/DATE: EU/1/11/699/001 - EU/1/11/699/002 20110720 |
| 2377536 | 300612 | Netherlands | ➤ Sign Up | PRODUCT NAME: 4-AMINOPYRIDINE, DAN WEL EEN DERIVAAT DAARVAN, IN HET BIJZONDER EEN ZOUT, SOLVAAT OF PRODRUG; REGISTRATION NO/DATE: EU/1/11/699/001-002 20110720 |
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
